News

Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe

·        

The agreement calls for a minimum of 500,000

bottles in sales over 18 months

·        

T-Cell Protect to invest 1 million euros in

Todos to support development of Tollovir, the Company’s 3CL Protease Inhibiting

Antiviral Drug Candidate

New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – November 24, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics

and related solutions company, together with its joint venture partner NLC

Pharma, Ltd., today announced that it has entered into an exclusive European licensing

& distribution agreement with T-Cell Protect Hellas S.A. (T-Cell Protect or

T-Cell) for a product based on its Tollovid® and Tollovid Daily 3CL protease

inhibitor and immune support dietary supplements. The product will be marketed

under the T-Cell Protect brand throughout 30 countries in Europe with the agreement

calling for a minimum of 500,000 bottles in sales over 18 months. T-Cell has

placed an initial purchase order for 50,000 bottles of the Tollovid Daily

product that is expected to meet the demand of an initial rollout to a subset

of the 11,000 stores located throughout Greece. More information about the

product can be found at
www.tcellprotect.com.

Under the terms of the agreement, T-Cell Protect will purchase finished product

at wholesale from Todos until such time as T-Cell Protect establishes

manufacturing capabilities at a facility it currently operates in Greece to

support the European market. At such time, Todos will then receive double-digit

royalties on the sales of the licensed product manufactured by T-Cell Protect. The

Company anticipates revenue to be generated from this agreement beginning in

the current quarter. 

Concurrent with this announcement, T-Cell Protect has made

an investment of 1 million euros in Todos Medical to support the
clinical development of Tollovir, the

Company’s
3CL protease inhibiting antiviral drug candidate, and has also received exclusive

marketing rights for Tollovir in Greece. T-Cell Protect intends on initiating the

process for conditional Emergency Use Authorization of Tollovir to meet the

increasing demand for the prevention and treatment of Coronaviruses, including

COVID-19.

We are very

excited to introduce and launch this new
daily dietary supplement to the

European Market based on the
Tollovid dietary supplement formulas for people

looking for additional targeted immune support,” said


Themis Filippopoulos, President & CEO of T-Cell Protect
. “It was

clear to us that we should focus on natural supplements because it’s an area that

we are aligned with and where we believe we can make a real difference to

people’s lives across the world. With consumers becoming increasingly more

focused on immune support products that utilize natural ingredients, we believe

that the formulations utilized in the Tollovid products will ideally position our

new T-Cell Protect supplement products to
capture a significant market

share for the rising class of 3CL protease inhibitors.
We are

also excited to invest in the development of Tollovir, especially
with

the recent significant increase in interest in 3CL protease inhibitor antiviral

products. We intend to work diligently with the team at Todos to secure market

authorization as quickly as possible.”

Mr. Filippopoulos continued, “We expect to see very strong

demand in Greece and the rest of the European market as people are looking for

additional layers of immune support heading into the winter. Moving forward, we

will be using this initial period for the rest of 2021 and early 2022 to

prepare for a larger European rollout, initially in the 8 largest countries in

Europe that have been equally impacted by the Coronavirus pandemic, where we

have our strongest retail footprint after Greece, and thereafter the rest of

Europe. We believe that the Tollovid family of products marketed under the

T-Cell Protect brand will be extremely well received in Europe where people are

focused on more natural ways to support and maintain healthy immune function.

The potential for Tollovid and Tollovid Daily in Europe is quite significant

and we are excited to bring them to market.”

“We believe this distribution agreement & related

investment validates our commercial approach for our Tollovid and Tollovid

Daily products,” said Gerald E. Commissiong, President & CEO of Todos

Medical. “As we continue to make significant progress with our Tollovir 3CL

protease inhibiting biology programs, we believe this promising therapeutic will

have a significant impact on human health going forward.”

“We look forward to working with T-Cell Protect to bring our

game-changing therapeutic product candidate Tollovir to market to treat

patients with COVID-19 in Greece,” said Dr. Dorit Arad, Founder & Chief

Scientific Officer of NLC Pharma, Todos’ 3CL biology joint venture partner.

For more information, please visit www.todosmedical.com.

For more information on the Company’s CLIA/CAP certified lab Provista

Diagnostics, Inc. please visit www.provistadx.com.

About Tollovid® & Tollovid Daily

Tollovid and Tollovid Daily are dietary supplement products,

made from natural ingredients, that helps support and maintain healthy immune

function, and are also 3CL protease inhibitor products based upon in vitro

functional assays that show inhibition of 3CL protease activity. Tollovid’s 3CL

protease inhibition activity release criteria is at least twice as stringent as

Tollovid Daily’s 3CL protease inhibition release criteria. Tollovid has a 5-day

dosing regimen, with 4 doses of 3 pills taken each day that provides maximum

immune support. Tollovid Daily is a twice daily immune support product that is

designed to provide ongoing daily immune support for the person on the go.

About Tollovir®

Tollovir® is a 3CL protease inhibitor and anti-cytokine

therapeutic candidate for the treatment of the nidovirus subcategory of

coronaviruses that includes SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E.

Tollovir is made from all natural ingredients that are qualified to ensure

strong inhibition of the 3CL protease in vitro, as well as strong anti-cytokine

activity. Tollovir is currently in a Phase 2 clinical trial in Israel for the

treatment of patients hospitalized with COVID-19. Tollovir will be developed

for the treatment of hospitalized COVID-19 (severe and critical), moderate

COVID-19, long-haul COVID and potentially pediatric COVID-19.

About

T-Cell Protect Hellas S.A.

T-Cell Protect Hellas (www.tcellprotect.com), based in

Athens, Greece, is a European nutraceutical manufacturer and supplier of immune

support dietary supplement products that is led by a world-class management

team. The company has 11,000 stores throughout Greece.  Mr. Filippopoulos, the founder of the

company, has been in the natural supplement industry for over 35 years and has

launched some of the most well-known products in Europe with his vast retail

network relationships. T-Cell Protect is rolling out the Tollovid family of

Products under the T-Cell brand throughout Europe.

About

Todos Medical Ltd.

Founded in Rehovot, Israel with offices in

New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving

diagnostic solutions for the early detection of a variety of cancers. The

Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses

(TBIA) is a proprietary cancer-screening technology using peripheral blood

analysis that deploys deep examination into cancer’s influence on the immune

system, looking for biochemical changes in blood mononuclear cells and plasma.

Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have

received a CE mark in Europe. Todos recently acquired U.S.-based medical

diagnostics company Provista Diagnostics, Inc. to gain rights to its

Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID

testing and Provista’s proprietary commercial-stage Videssa® breast cancer

blood test.

Todos is also developing blood tests for the

early detection of neurodegenerative disorders, such as Alzheimer’s disease.

The Lymphocyte Proliferation Test (LymPro Test) is a diagnostic blood test

that determines the ability of peripheral blood lymphocytes (PBLs) and

monocytes to withstand an exogenous mitogenic stimulation that induces them to

enter the cell cycle. It is believed that certain diseases, most notably

Alzheimer’s disease, are the result of compromised cellular machinery that

leads to aberrant cell cycle re-entry by neurons, which then leads to

apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a

surrogate for neuronal cell function, suggesting a common relationship between

PBLs and neurons in the brain.

Todos has entered into distribution

agreements with companies to distribute certain novel coronavirus (COVID-19)

test kits. The agreements cover multiple international suppliers of PCR testing

kits and related materials and supplies, as well as antibody testing kits from

multiple manufacturers after completing validation of said testing kits and

supplies in its partner CLIA/CAP certified laboratory in the United States.

Additionally, Todos has entered into a joint venture with NLC Pharma to pursue

the development of diagnostic tests targeting the 3CL protease, as well as 3CL

protease inhibitors that target a fundamental reproductive mechanism of

coronaviruses.

For more information, please visit https://www.todosmedical.com/.

Forward-looking

Statements

Certain statements contained in this press

release may constitute forward-looking statements. For example, forward-looking

statements are used when discussing our expected clinical development programs

and clinical trials. These forward-looking statements are based only on current

expectations of management, and are subject to significant risks and

uncertainties that could cause actual results to differ materially from those

described in the forward-looking statements, including the risks and

uncertainties related to the progress, timing, cost, and results of clinical

trials and product development programs; difficulties or delays in obtaining

regulatory approval or patent protection for product candidates; competition

from other biotechnology companies; and our ability to obtain additional

funding required to conduct our research, development and commercialization

activities. In addition, the following factors, among others, could cause

actual results to differ materially from those described in the forward-looking

statements: changes in technology and market requirements; delays or obstacles

in launching our clinical trials; changes in legislation; inability to timely

develop and introduce new technologies, products and applications; lack of

validation of our technology as we progress further and lack of acceptance of

our methods by the scientific community; inability to retain or attract key

employees whose knowledge is essential to the development of our products;

unforeseen scientific difficulties that may develop with our process; greater

cost of final product than anticipated; loss of market share and pressure on

pricing resulting from competition; and laboratory results that do not

translate to equally good results in real settings, all of which could cause

the actual results or performance to differ materially from those contemplated

in such forward-looking statements. Except as otherwise required by law, Todos

Medical does not undertake any obligation to publicly release any revisions to

these forward-looking statements to reflect events or circumstances after the

date hereof or to reflect the occurrence of unanticipated events. For a more

detailed description of the risks and uncertainties affecting Todos Medical,

please refer to its reports filed from time to time with the U.S. Securities

and Exchange Commission.

Todos Corporate and

Investor Contact:

Richard

Galterio

Todos

Medical

732-642-7770

rich.g@todosmedical.com

Source link

The post Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe first appeared on Smallcaps Daily.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button